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Abstract
Background: Allergic reactions towards the birch major pollen allergen Bet v 1 are among the most common causes of
spring pollinosis in the temperate climate zone of the Northern hemisphere. Natural Bet v 1 is composed of a complex
mixture of different isoforms. Detailed analysis of recombinant Bet v 1 isoforms revealed striking differences in immunologic
as well as allergenic properties of the molecules, leading to a classification of Bet v 1 isoforms into high, medium, and low
IgE binding proteins. Especially low IgE binding Bet v 1 isoforms have been described as ideal candidates for desensitizing
allergic patients with allergen specific immunotherapy (SIT). Since diagnosis and therapy of allergic diseases are highly
dependent on recombinant proteins, continuous improvement of protein production is an absolute necessity.
Methodology: Therefore, two different methods for recombinant production of a low IgE binding Bet v 1 isoform were
applied; one based on published protocols, the other by implementing latest innovations in protein production. Both
batches of Bet v 1.0401 were extensively characterized by an array of physicochemical as well as immunological methods to
compare protein primary structure, purity, quantity, folding, aggregation state, thermal stability, and antibody binding
capacity.
Conclusion: The experiments demonstrated that IgE antibody binding properties of recombinant isoallergens can be
significantly influenced by the production method directly affecting possible clinical applications of the molecules.
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Introduction
IgE-mediated hypersensitivity reactions, the most common
cause of allergy, affect more than 25% of the population in
industrialized countries. Typically, the allergic response is directed
against environmental proteins, so called allergens that originate
from various sources including pollen, spores of moulds, food,
mites, cockroaches, and animal dander. The allergic disease is
typically divided into a sensitization phase, where patients do not
experience allergic symptoms but become primed to react with
certain allergenic molecules, and the immediate phase of the
allergic reaction. During sensitization allergen-specific B cells are
activated to produce and secrete IgE antibodies, which attach via
the high affinity receptor FceRI to the surface of mast cells and
basophils. Upon repeated allergen contact, cross-linking of the
IgE-FceRI on mast cells and basophils triggers degranulation and
release of vasoactive amines (i.e. histamine), lipid mediators (i.e.
prostaglandins, leukotrienes), chemokines, and cytokines. These
events characteristic for the immediate phase of the allergic
reaction cause the typical allergic symptoms, i.e. allergic rhinitis,
conjunctivitis, hay fever or asthma, eczema, allergen elicited
gastrointestinal diseases, and anaphylaxis [1,2]. Specific immuno-
therapy (SIT) constitutes the only curative approach to treat
allergic diseases. During SIT increasing doses of allergen are
administered to a patient, ideally followed by modulation of the
allergic immune response at the levels of antigen presenting cells,
T cells and B cells. Molecules suitable for SIT should address all
these arms of the immune system, and still not elicit adverse side
effects. To increase the safety profile of SIT the use of well-
standardized low IgE-binding recombinant allergens seems most
preferable [3,4]. Allergic reactions towards the birch major pollen
allergen Bet v 1 are among the most common causes of spring
pollinosis in the temperate climate zone of the Northern
hemisphere. Natural Bet v 1 represents a complex mixture of
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different isoforms and to date more than 30 have been identified
showing differences concerning allergenicity as well as immuno-
genicity [5,6,7]. Formerly, the isoforms have been termed
alphabetically from Bet v 1a to n, which has been replaced by a
numbering system appointing the isoforms from Bet v 1.0101 to
Bet v 1.3001. Furthermore, a detailed immunologic characteriza-
tion led to a classification of the Bet v 1 family in high, medium,
and low IgE binding molecules [8,9]. Based on this data, naturally
occurring low IgE binding Bet v 1 isoforms appeared most suitable
for safe application in SIT. In this context, the low IgE binding
birch pollen isoform Bet v 1.0401, formerly Bet v 1d, was most
detailed investigated [9]. Notably, all studies of Bet v 1 isoforms
have been performed with recombinant proteins, however,
external influences such as production, storage condition, or
buffer systems can manipulate the allergenic but also immunologic
properties of the molecules. For instance, thermal processing of
Bet v 1 results in unfolding of the molecule. This loss of the native
structure is accompanied by a loss of its IgE binding capacity [10].
Since IgE binding to Bet v 1 is highly fold-dependent, production
procedures can have direct impact on the allergenic properties of
the recombinant allergen preparation. Recently, Kahlert et al.
rendered the per se high IgE binding Bet v 1.0101 into a
hypoallergenic folding variant by treating the protein with basic
buffer during recombinant production [11].
The aim of the present work was to investigate how latest
innovations in protein production could influence the allergenic
properties of recombinant Bet v 1.0401 by comparing two
different production protocols. In view of the conformation-
dependent IgE binding properties of Bet v 1, the study focused on
investigating expression and purification parameters directly
impacting protein folding. Thus, one batch of Bet v 1.0401 was
produced from a cDNA clone of birch pollen RNA and expressed
at 37uC without further optimization according to previously
published methods with minor modifications [12,13,14]. The
overall yields of recombinant Bet v 1.0401 appeared adequate;
however, the protein had to be purified from bacterial inclusion
bodies and refolded during purification. Alternatively, an
expression and purification protocol based on an E. coli codon
optimized Bet v 1.0401 gene was established. Low temperature
expression led to increased amounts of soluble protein allowing
protein purification without a denaturation/renaturation step.
Both production batches were analyzed by an array of
physicochemical methods for primary structure, purity, quantity,
folding, aggregation state, and thermal stability [15] as well as
immunologically investigating antibody binding on solid surface
and in solution.
Material and Methods
Patients and Sera
Fagales pollen-allergic patients were selected on the basis of
typical case history, positive in vivo skin prick test, and in vitro IgE
detection (CAP system, Phadia AB, Uppsala, Sweden). Patients
with IgE values greater than class 3 were selected. The study was
approved by the Local Ethic Committee of the University of
Salzburg, and informed written consent was obtained from all
subjects included in the study.
Recombinant Reference Allergens
Recombinant Bet v 1.0101 (X15877), also known as Bet v 1a,
which shows an amino acid sequence identity of 95% with Bet v
1.0401, formerly termed Bet v 1d, was used as reference allergen.
The protein was purchased from Biomay AG (Vienna, Austria).
Bacterial Strains and Plasmids
For protein expression of Bet v 1.0401 (X77266) two constructs
were designed. Both constructs encoded for the same protein. For
the first construct the DNA sequence of Bet v 1.0401 obtained by
cDNA cloning of the birch pollen allergen from its natural source
was used. The second construct is based on an E. coli codon
optimized gene of Bet v 1.0401. Both genes were inserted into the
T7-based expression vector pET28b (Novagen, Merck Chemicals
Limited, Nottingham, UK). The E. coli strain BL21 (DE3)
(Stratagene, La Jolla, CA, USA) was used for production of
recombinant proteins.
Expression and Purification of Recombinant Bet v 1.0401
- Production Batch A
Bet v 1.0401 batch A was produced according to previously
published methods with minor modifications [12,13,14]. Therefore,
the cDNA of Bet v 1.0401 obtained from a birch pollen library was
inserted into the vector pET28b was used for production of
recombinant protein. Expression plasmids were freshly transformed
and E. coli BL21 (DE3) cells were grown in LB medium
supplemented with 25 mg/L kanamycin at 37uC to an OD600 of
0.8. After addition of 0.5 mM IPTG, expression of Bet v 1.0401 was
performed for 6 h at 37uC. Cells were harvested by low speed
centrifugation; inclusion bodies were prepared and resuspended in
10 mM imidazole pH 7.4, 100 mM NaCl, supplemented with
10 mMdithioerythritol (DTE) to reduce intermolecular interactions
of Bet v 1.0401 via its single cysteine. Proteins were solubililzed by
addition of 10 M NaOH under constant stirring until a pH of 13
was reached. After 5 min incubation citric acid was added to lower
the pH to 8.6. The solution was centrifuged at 18.000 g for 10 min
followed by addition of 20 mM DTE and incubation 1 h at 37uC.
Afterwards solid NaCl and NaH2PO4 were added under constant
stirring on ice to final concentrations of 1 M and 0.2 M,
respectively. Bet v 1.0401 was purified by hydrophobic interaction
chromatography using a 100 ml Phenyl sepharose column (GE
Healthcare, Little Chalfont, UK). The protein was eluted with
25 mM Tris/HCl pH 9.3, 8% (v/v) 2-propanol and resulting
fractions containing Bet v 1.0401 were pooled and dialyzed against
10 mM sodium phosphate pH 7.2, 2 mM b–mercaptoethanol.
Final purification was performed by HPLC using a Hypersil C-8
column (Thermo Fisher Scientific Inc., Waltham, MA, USA) with a
flow rate of 5 ml/min. Bet v 1.0401 was eluted using a 60 ml
gradient 0–80% buffer B from 0.1% trifluoroacetic acid to 0.1%
trifluoroacetic acid, 90% (v/v) 2-propanol (Table 1). Purified
recombinant protein was dialyzed against 10 mM sodium phos-
phate buffer pH 7.4, freeze dried, and stored at 220uC.
Expression and Purification of Recombinant Bet v 1.0401
- Production Batch B
Codon-optimized Bet v 1.0401 inserted into the vector pET28b
was used for production of recombinant protein. Expression
plasmids were freshly transformed and E. coli StarTM BL21 (DE3)
(Invitrogen, Paisley, UK) cells grown at 37uC in 4L LB supp.
medium (1% (w/v) peptone, 0.5% (w/v) yeast extract, 0.5% (w/v)
NaCl, 2 mM MgSO4, 1% (v/v) glycerol, 0.2% (w/v) ammonium
sulfate, 10 mM sodium phosphate pH 7.4) supplemented with
25 mg/L kanamycin at 37uC to an OD600 of 0.8. After addition of
0.5 mM IPTG expression of Bet v 1.0401 was performed for 18 h
at 16uC. Cells were harvested by low speed centrifugation and
resuspended in 25 mM sodium phosphate buffer pH 7.4, 0,1% (v/
v) Triton X-100, 0.5 M urea. Additionally, solid NaCl and
NaH2PO4 were added under constant stirring on ice to final
concentrations of 1 M and 0.5 M, respectively. After centrifuga-
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tion at 15.000 g, the solution was filtered through a 0.45 mm filter
and soluble Bet v 1.0401 was purified by hydrophobic interaction
chromatography using a 100 ml Phenylsepharose column (GE
Healthcare). Urea was removed by applying a gradient of 200 ml
using 0.2 M NaH2PO4, 1 M NaCl, pH 4.2. The protein was
eluted with 25 mM Tris/HCl pH 9.3, 8% (v/v) 2-propanol and
resulting fractions containing Bet v 1.0401 were pooled and
dialyzed against 20 mM imidazole pH 7.4, 4% (v/v) 2-propanol.
Final purification was performed by anion exchange chromatog-
raphy using a 100 ml DEAE sepharose column (GE Healthcare).
Bet v 1.0401 was eluted with 20 mM imidazole pH 7.4, 4% (v/v)
2-propanol, 250 mM NaCl using a 1200 ml gradient. All
chromatographic steps were performed with an A¨KTA Prime
(GE Healthcare) using a flow rate of 2.2 ml/min (Table 1).
Purified recombinant protein was dialyzed against 10 mM sodium
phosphate buffer, pH 7.4, freeze dried, and stored at 220uC.
SDS-PAGE
E. coli lysates as well as purified proteins were analyzed by
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) according to the method described by Laemmli [16], using
either 15% gels or alternatively 12–24% gradient gels. Proteins
were visualized by staining with Coomassie Brilliant Blue R-250
(Biorad, Hercules, CA, USA).
Physicochemical Characterization of Recombinant
Proteins
Protein identity was determined by mass spectrometry using a
Quadrupole time-of-flight mass spectrometer with electrospray
ionization (ESI-QTOF-MS) (Waters Corp., Milford, MA, USA).
Therefore, proteins were separated by 2D gel electrophoresis and
Coomassie-stained spots were excised from 2D gels [17]. Spots
were analyzed by densitometry using Photoshop CS3 (Adobe
Systems Incorporated, San Jose, CA, USA). Intact proteins were
extracted and directly infused into a Global Ultima Q-TOF
instrument (Waters Corp., Milford, MA, USA) with electrospray
ionization [17]. Protein secondary structure content was deter-
mined by circular dichroism (CD) spectroscopy. CD spectra were
recorded with a JASCO J-815 spectropolarimeter fitted with a
PTC-423S Peltier type single position cell holder in appropriate
buffers (Jasco, Tokyo, Japan). Homogeneity and aggregation
behaviour in solution of Bet v 1.0401 were performed by online
high performance-size exclusion chromatography (HPSEC)–light
scattering and dynamic light scattering (DLS), respectively, as
described elsewhere [15].
Fluorescence Spectroscopy
8-anilino-1-naphtalenesulfonic acid (ANS) binding experiments
with recombinant allergens were performed using 10 mM of the
respective allergen and increasing concentrations of ANS,
preparing aliquots for each data point. Fluorescence measure-
ments were performed in 5 mM sodium phosphate buffer pH 7.4
at 450 nm using an excitation wavelength of 370 nm in a Tecan
Infinite 200 microplate reader (Tecan Group Ltd., Ma¨nnedorf,
Switzerland) [18]. Nonlinear regressions of ligand binding data as
well as dissociation constants (Kd) were calculated using Sigmaplot
11.0 (Systat Software Inc., San Jose, CA, USA).
ELISA Experiments
Maxisorp plates (NUNC, Wiesbaden, Germany) were coated
with titrations 2 mg/ml protein in PBS in a total volume of 50 ml
overnight at 4uC. After washing and blocking, patients’ sera
diluted 1 to 5 in 50 ml were added overnight at 4uC. Bound IgE
was detected with alkaline phosphatase-conjugated monoclonal
anti-human IgE antibodies (BD Biosciences, Franklin Lakes, NJ,
USA) in a colorimetric assay. All measurements were performed as
triplicates. Results are presented as mean OD values after baseline
correction.
Mediator Release from Rat Basophilic Leukemia Cells (RBL
Cells)
The allergenic potential of recombinant pollen allergens was
measured by degranulation assays using rat basophil leukemia cells
RBL-2H3 transfected with the human high-affinity IgE receptor
(FceRI). Briefly, RBL-2H3 cells, were passively sensitized with
human serum IgE from birch pollen-allergic patients. After
washing, degranulation was triggered by addition of serial dilutions
of the respective allergens. b-hexosaminidase release into the
supernatant was measured by enzymatic cleavage of the
fluorogenic substrate 4-methylumbelliferyl-N-acetyl-b-D-glucosa-
minide and expressed as % of total enzyme content of Triton X-
100-treated cells [19].
Statistical Analysis
Statistical evaluation of ELISA experiments with human serum
samples (n=13) and rat basophil mediator release assays using sera
of allergic individuals (n=8) were calculated with paired samples t-
test. A value of P,0.05 was considered statistically significant.
Results
Production Batch A - Purification of Bet v 1.0401 under
Denaturing Conditions Followed by Refolding
Recombinant Bet v 1.0401 was expressed from the plasmid
pET28b as non-fusion protein in E. coli BL21 (DE3) at 37uC. After
disruption of the cells, Bet v 1.0401 was found in inclusion bodies,
which were dissolved by addition of 10 M sodium hydroxide to
increase the pH of the solution to 13. This resulted in denaturation
Table 1. Recombinant production of Bet v 1.0401.
Production batch A Production batch B
Gene Bet v 1.0401, plant codon usage Bet v 1.0401, E. coli codon usage
Expression plasmid, cloning sites pET28b, 59 Nco I, 39 Eco RI pET28b, 59 Nco I, 39 Eco RI
Bacterial cells BL21 (DE3) BL21 StarTM (DE3)
Expression conditions 37uC, 6 h 16uC, 18 h
Extraction inclusion bodies with NaOH, pH 13 soluble proteins with 0.5 M Urea
Chromatography HIC, reversed phase HPLC HIC, IEX
doi:10.1371/journal.pone.0008457.t001
Birch Pollen Isoallergens
PLoS ONE | www.plosone.org 3 December 2009 | Volume 4 | Issue 12 | e8457
of Bet v 1.0401 (Figure 1), however, the protein refolded after
lowering the pH to 8.5 using citric acid. Thereafter, Bet v 1.0401
was purified by hydrophobic interaction chromatography followed
by a polishing step using reversed phase chromatography on a
HPLC (Figure 2). 1 liter E. coli culture yielded 38 mg pure Bet v
1.0401.
Production Batch B - Purification of Bet v 1.0401 without
Denaturation/Renaturation Results in Improved Solubility
and Enhanced Protein Yields
To increase the yield of recombinant Bet v 1.0401 in E. coli
especially at low expression temperature, a codon-optimized gene
was designed [20], integrated in a pET28b plasmid, and
transformed into BL21 StarTM (DE3) cells. This E. coli strain has
been designed to further improve protein yields of T7-based
expression systems. Cells were grown at 37uC in modified LB
medium to an OD600 of 0.8 in shaking flasks and after induction
protein expression was performed at 16uC for 18 h [21]. In
contrast to batch A, where Bet v 1.0401 was deposited in classical
inclusion bodies by E. coli cells, low-temperature production of Bet
v 1.0401 resulted in the formation of non-classical inclusion
bodies. Unlike classical inclusion bodies, where inactive recombi-
nant proteins form large aggregates, non-classical inclusion bodies
constitute of large amounts of most likely correctly folded over-
expressed protein [22]. Bet v 1.0401 batch B was extracted from
such non-classical inclusion bodies under mild conditions by
addition of 0.5 M urea, which did not introduce any change in the
molecule’s fold (Figure 1). Further purification was performed
using hydrophobic interaction and anion exchange chromatogra-
phy (Figure 2). Applying the optimized production method, 1 liter
E. coli culture yielded 80 mg pure Bet v 1.0401.
Different Production Methods Directly Influence the
Primary Structure of Bet v 1.0401
As posttranslational modifications often influence the pI of
proteins, thus, resulting in multiple spots of differently charged
variants of the same protein, both Bet v 1.0401 batches were
evaluated by 2D gel electrophoresis. Batch A of Bet v 1.0401
resulted in 4 spots: (i) spot 1 with a relative abundance of 47.2% of
total Bet v 1.0401 showed an average mass of 17417.2 Da,
whereas (ii) spot 2 (37.8%) and (iii) spot 3 (12.5%) showed a distinct
mass shift of +1 (17418.2 Da) and +2 Da (17419.2 Da), respec-
tively. These mass shifts are the result of deamidation of Asn
frequently observed for members of the Bet v 1 family [15,23].
Spot 4 accounted for 2.5% of Bet v 1.0401 batch A. According to
the pI of this spot a negative charge of Bet v 1.0401 was either
masked or removed, which could be a result of either a C-terminal
modification or a conformer of Bet v 1.0401. However, peptide
sequencing of the corresponding spot could not detect any
modification (sequence coverage of 85,5%). In case of batch B,
only 3 spots were visible on the 2D gel: (i) spot 1 with the correct
mass of 17417.2 Da containing 72.5% and (ii) spot 2 with a mass
shift of +1 Da (17418.2 Da) containing 22.6% of Bet v 1.0401.
Spot 3, which corresponded to spot 4 of batch A, accounted for
4.9% of Bet v 1.0401 batch B (Figure 3).
Bet v 1.0401 Produced under Denaturing Conditions
Forms High Molecular Weight Aggregates
An important parameter for quality assessment of protein
solutions is represented by the aggregation behavior, which was
investigated for both Bet v 1.0401 production batches using online
HPSEC-light scattering and DLS. When subjected to chromatog-
raphy several fractions could be resolved for Bet v 1.0401
production batch A reflecting different aggregation states of the
protein (Figure 3). Interestingly, production under denaturing
conditions resulted in formation of 2% multimers with a MW of
more than 2,000 kDa, 12% small oligomers of 70–80 kDa
(primarily tetramers), and .80% monomers. The aggregation
behavior of production batch A was even more pronounced when
investigated by DLS, a batch technique that does not disrupt
potentially reversible aggregates due to shear forces or diluting
effects characteristic for high pressure chromatographic tech-
niques. Using DLS, one third of high MW aggregates
(.2,000 kDa) was observed for this batch. The other peak at a
hydrodynamic radius of 2.6 nm resulted from an unresolved
mixture of monomers and small oligomers, which was also
detected by HPSEC. In contrast, production conditions avoiding a
denaturation/renaturation step prevented an elevated aggregation
tendency. More than 99% of Bet v 1.0401 production batch B
appeared monomeric in online HPSEC-light scattering and less
than 3% of high MW aggregates were determined by DLS
experiments of Bet v 1.0401 production batch B.
Secondary Structure Elements and Folding Properties of
Bet v 1.0401 Batches Revealed Remarkable Differences
Secondary structure elements of recombinant proteins were
analyzed by CD spectroscopy. Since natural Bet v 1.0401 can only
be obtained in minute amounts from birch pollen and therefore
has never been purified no reference CD is available for the
allergen. Thus, the CD spectra of both Bet v 1.0401 production
batches were compared to the spectrum obtained from Bet v
1.0101, an isoform which was demonstrated to produce identical
Figure 1. Circular dichroism analysis of Bet v 1.0401. CD spectra
of Bet v 1.0401 batch A were recorded in 10 mM sodium phosphate
after addition of sodium hydroxide pH 13 (dashed line) and after
refolding in 10 mM sodium phosphate pH 7.4, Spectra of batch B were
recorded in 10 mM sodium phosphate pH 7.4, 0.5 M Urea (dashed dot
dotted line) and after removal of the Urea in 10 mM were recorded in
10 mM Data are presented as mean residue molar ellipticity [H]MRW at a
given wavelength and baseline corrected. For all measurements quartz
cuvettes with a path length of 0.1 cm were used. Far UV CD spectra
were recorded at 20uC, with a band width of 1 nm, a response time of
1 sec and a data pitch of 1 nm. The measurement range was between
190–260 nm. Each spectrum represents an average of five consecutive
scans.
doi:10.1371/journal.pone.0008457.g001
Birch Pollen Isoallergens
PLoS ONE | www.plosone.org 4 December 2009 | Volume 4 | Issue 12 | e8457
CD spectra as natural Bet v 1 and therefore, providing an ideal
reference candidate [11]. The CD spectrum of Bet v 1.0401 batch
B was comparable to the spectrum obtained from Bet v 1.0101.
However, the spectrum obtained from Bet v 1.0401 batch A,
which has been denatured for protein purification, showed a
distinct shift of the CD curve intersection at 0 [H]MRW units from
202 to 198 nm (Figure 3). This might be an indication for a slightly
alternative fold of batch A, or for a mixture of folded an unfolded
proteins coexisting in this production batch. Next, the melting
points (Tm) were calculated for both batches of Bet v 1.0401.
Therefore, the protein was progressively heated with a tempera-
ture slope of 1uC/min and the unfolding of Bet v 1.0401 was
monitored at a wavelength of 222 nm. Bet v 1.0401 produced
without a denaturation/renaturation step showed a Tm of
61.7060.31uC, whereas denaturation and renaturation of Bet v
1.0401 during recombinant production resulted in a 3.15uC lower
Tm of 58.5560.63uC.
Recombinant Production Can Influence Ligand Binding
Properties of Bet v 1.0401
Bet v 1 has a Y-shaped, solvent accessible hydrophobic cavity
traversing the core of the molecule, capable of binding a wide
range of ligands. 8-anilino-1-naphtalenesulfonic acid (ANS), a
substrate, which is essentially non-fluorescent, however, displays
fluorescence when bound to hydrophobic patches of proteins, has
been reported to bind this cavity of Bet v 1 [24,25]. Experiments
revealed that ANS binds to both production batches of Bet v
1.0401 with a binding stoichiometry of 2 to 1. However, the
dissociation constant (Kd) was increased for ligand binding of
batch A (Kd= 24.46 mM) when compared to batch B
(Kd= 21.23 mM) (Figure 3). This observation could be a result
of the tendency of batch A to form high molecular weight
aggregates, which could obstruct the access to the cavity and
hamper ligand binding.
Different Production Methods Directly Affect IgE Binding
Properties of Bet v 1.0401
To investigate IgE antibody binding of Bet v 1.0401 ELISA
experiments with sera from 13 birch pollen-allergic patients were
performed. Compared to the high IgE binding reference allergen
Bet v 1.0101, both production batches of Bet v 1.0401 showed
significantly reduced binding of serum IgE (P,0.01) (Figure 4).
Interestingly, Bet v 1.0401 batch A did not show any IgE binding
activity, whereas Bet v 1.0401 batch B bound significantly more
serum IgE (P,0.01). The altered structure of batch A could
facilitate further distortion of the molecule upon binding to the
surface of the ELISA plate, which in consequence, could hinder
patients’ serum IgE binding in the assay.
Recombinant Bet v 1.0401 Produced under Denaturing
Conditions Shows Lower Allergenic Activity
Rat basophils loaded with sera from birch pollen-allergic
patients (n=8) were used to determine the allergenic activity of
the two Bet v 1.0401 batches. Allergen amounts necessary to
trigger half maximal release of inflammatory mediator were
determined. The half maximal mediator release per patient was
defined by the dose-dependent mediator release curve of rBet v
1.0101, which was used as high IgE binding reference allergen. Bet
v 1.0401 batch B showed only a 2 fold decreased allergenic activity
when compared to Bet v 1.0101. However, Bet v 1.0401 batch A
displayed an 11-fold (P,0.05) reduced IgE binding activity when
compared to Bet v 1.0101 and a 6-fold (P,0.05) reduced activity
when compared to Bet v 1.0401 batch B (Figure 4). Though, the
three allergens could elicit comparable maximal mediator release
of the sensitized basophils.
Discussion
As alternative production procedures can have dramatic effects
on protein folding, during the present work two different
recombinant preparations of the birch pollen allergen isoform
Bet v 1.0401 were analyzed. Batch A based on a denaturing step
during purification, applying a method previously published for
the purification of Bet v 1 isoforms with minor modifications
[12,13,14], and batch B prepared from soluble bacterial lysate
following an optimized production protocol. An array of
physicochemical as well as immunological investigations to analyze
identity, quantity, homogeneity, folding and aggregation behavior,
as well as biological activity was applied to both Bet v 1.0401
batches.
Figure 2. Purification of Bet v 1.0401. SDS-PAGE analysis of Bet v 1.0401 purification. Bet v 1.0401 batch A was purified from E. coli lysates
using a denaturing step during production, batch B was purified from soluble bacterial lysate. Production batch A, lane 1, total bacterial lysate; lane 2,
soluble bacterial lysate; lane 3, fraction after basic denaturation; lane 4, salt precipitated fraction; lane 5 hydrophobic interaction chromatography;
lane 6, reversed phase chromatography. Production batch B, lane 1, total bacterial lysate; lane 2, soluble bacterial lysate; lane 3, salt precipitated
pellet; lane 4, salt precipitated fraction; lane 5, hydrophobic interaction chromatography; lane 6, anion exchange chromatography.
doi:10.1371/journal.pone.0008457.g002
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Analysis of the primary structure of Bet v 1.0401 using a
combination of isoelectric focusing and mass spectrometry
revealed batch A to be composed of a mixture of 4 differently
charged Bet v 1.0401 species, amongst others being a result of
deamidation of Asn. Interestingly, the vast majority of batch B
consisted of a single protein species showing no posttranslational
modifications. Bet v 1.0401 batch A showed a clear tendency to
form high molecular weight aggregates ranging from smaller
oligomers (12%) to large multimeric complexes (2%), whereas
more than 99% of batch B appeared monomeric when analyzed
by online HPSEC-light scattering. CD spectroscopy revealed
changes in secondary structure of Bet v 1.0401 batch A, which also
manifested in a lower melting point of the protein. These changes
in the secondary structure might provide an explanation for
increased aggregation of the allergen. In contrast, batch B showed
a CD spectrum typical for Bet v 1. Crystallization of several Bet v 1
isofoms revealed that the core of the protein is traversed by Y-
shaped, solvent accessible, hydrophobic cavity capable of binding
Figure 3. Physicochemical characterization of Bet v 1.0401. Bet v 1.0401 batches were separated by 2D gel electophoresis. Gels were
coomassie-stained, numbered spots were analyzed by MS and assigned to respective charge variants (A). ANS titration curves were recorded in
10 mM sodium phosphate (pH 7.4) using excitation and emission wavelengths of 370 and 450 nm, respectively. Solid lines represent nonlinear
regressions of the experimental data (B). Circular dichroism spectra are presented as mean residue molar ellipticity [H]MRW at a given wavelength and
baseline corrected. Bet v 1.0101 was used as reference for Bet v 1-like fold (C). Aggregation behaviour of Bet v 1.0401 batches was investigated by
dynamic light scattering (DLS) in aqueous solution at a concentration of 1 mg/ml (D) and by online HPSEC-light scattering analysis operated at
0.5 ml/min in 0.1 M sodium phosphate pH 6.5, 150 mM sodium chloride (E). Analysis of Bet v 1.0401 batch A with DLS showed higher aggregation
tendency (66% RH of 2.660.3 nm and 34% RH of 1668 nm) compared to batch B (98% RH of 2.160.3 nm and 2% RH of 16610 nm) (D). In online
HPSEC-light scattering of batch A, molecular weight values of 70–80 kDa and 17 kDa were determined from refractive index and right-angle light
scattering signals from peaks of oligomeric and monomeric Bet v 1.0401 eluting at retention times (vret) of 9.1 and 10.3 ml, respectively. For batch B
one peak at vret of 10.3 ml with a molecular weight of 17 kDa was detected.
doi:10.1371/journal.pone.0008457.g003
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a wide range of ligands [24,25,26]. Therefore, the ability of ligand
binding was investigated using the fluorescent substrate ANS. The
dissociation constant (Kd) for ANS was shown to be higher in Bet
v 1.0401 batch A than in batch B, which might be again an
indication of fold changes of the protein. Additionally, patients’
serum IgE binding was assessed in ELISA experiments including
Bet v 1 isoform 0101, which was demonstrated to be suitable as
reference material for analysis of IgE binding to Bet v 1 [27], as
positive control. Both batches of Bet v 1.0401 showed a
significantly reduced IgE binding capacity when compared to
Bet v 1.0101 (32-fold versus 9-fold reduction for batch A and B,
respectively). This is explainable, since Bet v 1.0401 represents a
low IgE binding Bet v 1 isoform, whereas Bet v 1.0101 is a strong
IgE binding molecule [7]. Still, Bet v 1.0401 batch B could bind
patients serum IgE to some extent, however, IgE binding to batch
A was not detectable. This could be confirmed by basophil
mediator release assays demonstrating double the amount of Bet v
1.0401 batch B and 11 fold of Bet v 1.0401 batch A to be
necessary to trigger a similar mediator release when compared to
Bet v 1.0101. So far, only conformation-dependent IgE epitopes
have been identified on Bet v 1 [10]. Therefore, it seems likely that
the documented conformational changes introduced in Bet v
1.0401 batch A by denaturation of the protein during recombinant
production account for the abrogated IgE binding capacity of the
molecule. Thus, we speculate that the observed IgE binding
potential of batch B reflects the IgE binding capacity of natural Bet
v 1.0401, whereas the low IgE binding activity of batch A seems
rather artificial. Using allergen extracts for allergy diagnosis and
therapy is associated with problems in extract standardization and
often incontrollable batch-to-batch variability [27,28]. The use of
purified natural allergens to replace allergen extracts is also
problematic, since natural allergen preparations can be contam-
inated with other allergenic molecules from the same source, and
moreover, complex isoform combinations or post-translational
modifications complicate the production of natural allergen
preparations hindering the formulation of a standardized product.
Therefore, the field of allergology is highly dependent on
recombinant molecules and special attention should be paid on
the quality of these products. The present study could demonstrate
the influence of production procedures on the allergenic properties
of an isoform of the major birch pollen allergen Bet v 1. The two
different production methods had direct impact on primary and
secondary structure of the allergen resulting in modified
immunologic behavior. These results emphasize the necessity of
certified biological reference preparations for allergenic products.
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